The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Syphilis predicts HIV incidence among men and transgender women who have sex with men in a preexposure prophylaxis trial.
Open accessAbstract
BACKGROUND: Syphilis infection may potentiate transmission of human immunodeficiency virus (HIV). We sought to determine the extent to which HIV acquisition was associated with syphilis infection within an HIV preexposure prophylaxis (PrEP) trial and whether emtricitabine/tenofovir (FTC/TDF) modified that association. METHODS: The Preexposure Prophylaxis Initiative (iPrEx) study randomly assigned 2499 HIV-seronegative men and transgender women who have sex with men (MSM) to receive oral daily FTC/TDF or placebo. Syphilis prevalence at screening and incidence during follow-up were measured. Hazard ratios for the effect of incident syphilis on HIV acquisition were calculated. The effect of FTC/TDF on incident syphilis and HIV acquisition was assessed. RESULTS: Of 2499 individuals, 360 (14.4%) had a positive rapid plasma reagin test at screening; 333 (92.5%) had a positive confirmatory test, which did not differ between the arms (FTC/TDF vs placebo, P = .81). The overall syphilis incidence during the trial was 7.3 cases per 100 person-years. There was no difference in syphilis incidence between the study arms (7.8 cases per 100 person-years for FTC/TDF vs 6.8 cases per 100 person-years for placebo, P = .304). HIV incidence varied by incident syphilis (2.8 cases per 100 person-years for no syphilis vs 8.0 cases per 100 person-years for incident syphilis), reflecting a hazard ratio of 2.6 (95% confidence interval, 1.6-4.4; P < .001). There was no evidence for interaction between randomization to the FTC/TDF arm and incident syphilis on HIV incidence. CONCLUSIONS: In HIV-seronegative MSM, syphilis infection was associated with HIV acquisition in this PrEP trial; a syphilis diagnosis should prompt providers to offer PrEP unless otherwise contraindicated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similar to other STIs, multiple partners, anonymous partners, condomless sex, and substance use are all associated with HIV infection (193–196).”
From Sexually Transmitted Infections Treatment Guidelines, 2021 (2021) · cites this paper as [196]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A. Y., Vargas, L., Goicochea, P., Casapía, M., Guanira-Carranza, J. V., Ramirez-Cardich, M. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1011205 · Cited by 5,096
Self-citationAntiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Baeten, J. M., Donnell, D., Ndase, P., Mugo, N. R., Campbell, J. D., Wangisi, J., Tappero, J. W., Bukusi, E. A., Cohen, C. R., Katabira, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1108524 · Cited by 3,256
Fleming, D. T., & Wasserheit, J. N. (1999) · Sexually Transmitted Infections · doi:10.1136/sti.75.1.3 · Cited by 2,271
Sexually transmitted diseases treatment guidelines
Burstein, G. R., & Workowski, K. (2003) · Current Opinion in Pediatrics · doi:10.1097/00008480-200308000-00006 · Cited by 2,077
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Thigpen, M. C., Kebaabetswe, P. M., Paxton, L. A., Smith, D. K., Rose, C. E., Segolodi, T. M., Henderson, F. L., Pathak, S. R., Soud, F. A., Chillag, K. L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110711 · Cited by 1,996
Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines
Workowski, K., & Berman, S. M. (2007) · Clinical Infectious Diseases · doi:10.1086/511430 · Cited by 1,977
Sexually Transmitted Diseases 7982 Treatment Guidelines
Workowski, K., & Berman, S. M. (1982) · American Pharmacy · doi:10.1016/s0160-3450(16)31823-2 · Cited by 1,577
Choopanya, K., Martin, M., Suntharasamai, P., Sangkum, U., Mock, P. A., Leethochawalit, M., Chiamwongpaet, S., Kitisin, P., Natrujirote, P., Kittimunkong, S., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61127-7 · Cited by 1,463
Wasserheit, J. N. (1992) · PubMed · Cited by 1,245
Anderson, P. L., Glidden, D. V., Liu, A., Buchbinder, S., Lama, J. R., Guanira, J. V., McMahan, V., Bushman, L. R., Casapía, M., Montoya, O., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004006 · Cited by 1,054
Self-citation
Research works printed but not linked: 4
- 2012, Science Translational Medicine, 4, 151ra25
- 2010, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control, 59, 1
- 2012, MMWR. Morbidity and mortality weekly report, 61, 586
- 2011, MMWR. Morbidity and mortality weekly report, 60, 65
Cited by
Sorted by citations
Sexually Transmitted Infections Treatment Guidelines, 2021
Workowski, K. A., Bachmann, L. H., Chan, P. A., Johnston, C. M., Muzny, C. A., Park, I., Reno, H., Zenilman, J. M., & Bolan, G. A. (2021) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr7004a1 · Cited by 3,018
Sexually Transmitted Diseases Treatment Guidelines, 2010
Workowski, K., & BOLAN, G. A. (2011) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2011.04.006 · Cited by 2,074
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
Landovitz, R. J., Donnell, D. J., Clement, M. E., Hanscom, B. S., Cottle, L. M., Coelho, L. E., Cabello, R. L., Chariyalertsak, S., Dunne, E. F., Frank, I., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101016 · Cited by 934
Self-citationVolk, J. E., Marcus, J. L., Phengrasamy, T., Blechinger, D., Nguyen, D. P., Follansbee, S., & Hare, C. B. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ778 · Cited by 489
Ong, J. J., Baggaley, R. C., Wi, T. E., Tucker, J. D., Fu, H., Smith, M. K., Rafael, S., Anglade, V., Falconer, J., Ofori-Asenso, R., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.17134 · Cited by 173
Metadata
- Authors
- Solomon, M. M., Mayer, K. H., Glidden, D. V., Liu, A. Y., McMahan, V. M., Guanira, J. V., Chariyalertsak, S., Fernandez, T., Grant, R. M., Bekker, L.-G., Buchbinder, S., Casapia, M., Chariyalertsak, S., Guanira, J., Kallas, E., Lama, J., Mayer, K., Montoya, O., Schechter, M., Veloso, V., & for the iPrEx Study Team
- Affiliations
- Gladstone Institutes (US)
- University of California, San Francisco (US)
- San Francisco Department of Public Health (US)
- Chiang Mai University (TH)
- Corresponding author
- Solomon, M. M.
- ORCID
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-06-13
- Volume
- 59
- Issue
- 7
- Pages
- 1020-1026
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- PMC
- PMC4166980
- OpenAlex
- W2114094089
- Cited by
- 159
- References
- 42
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 13 · 2023: 6 · 2022: 5 · 2021: 10 · 2020: 18 · 2019: 22 · 2018: 19 · 2017: 18 · 2016: 14 · 2015: 19 · 2014: 6
- FWCI
- 13.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Clinical Infectious Diseases (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Arca - Repositório Institucional da Fiocruz (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Bill and Melinda Gates Foundation
- Gilead Sciences
- Gladstone Institutes
- National Institutes of Health (5u01ai064002-07, UL1TR000004)
- University of California, San Francisco (UL1RR024131)
- National Institute of Allergy and Infectious Diseases (U01-AI064002, R01AI062333, RR024131, UO1 AI64002, AI64002, AI062333, T32AI007641)
- National Center for Research Resources (UL1RR024131)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
- Health Sciences › Medicine › Infectious Diseases › Syphilis Diagnosis and Treatment
- Health Sciences › Medicine › Epidemiology › HIV, Drug Use, Sexual Risk
- Keywords
- syphilis, HIV acquisition, HIV pre-exposure prophylaxis, tenofovir/emtricitabine, men who have sex with men, transgender women, HIV transmission
- MeSH terms
- Emtricitabine, Tenofovir, Adenine, Adult, Deoxycytidine, Female, Humans, Male, Middle Aged, Placebos, Syphilis, HIV Infections, Incidence, Prevalence, Treatment Outcome, Homosexuality, Male, Anti-HIV Agents, Young Adult, Organophosphonates, Transgender Persons, Pre-Exposure Prophylaxis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
